Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection

Inclusion Criteria: * Antibiotic therapy for a minimum of 3 days and a maximum of 14 days * Expected to remain hospitalized for a minimum of 5 days * Patients who have received less than 36 hours of antibiotic therapy * Negative pregnancy test at screening * Obtained his/her informed consent after verbal and written information * Patients having a telephone available (mobile, work, home) * Patients having a fridge at home Exclusion Criteria: * Pregnant or breastfeeding women * Patients presenting with active diarrhea (3 or more liquid stools per 24 hour period). * Patients with a history of daily consumption of probiotics, fermented milk and/or yogurt; * Patients known to have shown a previous reaction, including anaphylaxis, to any substance in composition of the study product (i.e. Non-medicinal ingredients: Cellulose, hypromellose, magnesium stearate (vegetal source), ascorbic acid, Colloidal silicon dioxide) * Patients presenting with an active, non-controlled intestinal disease such as Crohn's Disease or ulcerative colitis; * A previous documented C. Difficile infection \< 3 months prior to study initiation ; * Ostomized patients, parenteral nutrition users * Patients with an immunosuppressive therapy or any health condition causing immunosuppression (including haematological malignancies, acquired immune deficiency syndrome (AIDS)) * Ongoing or recent use of antibiotic therapy in the 30 days prior to the study product first administration. * Patients with planned administration of antibiotics other than broad spectrum Penicillin, Cephalosporin or Clindamycin for the treatment of an infection; * Patients with concomitant participation in another clinical trial; * Patients who are not likely to comply with study requirements